1. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26(2):192–6.
2. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products (2000). Points to consider on switching between superiority and non-inferiority. London, UK.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf
, last accessed on 12/20/2018.
3. European Medicines Agency - Committee for Medicinal Products for Human Use (2006). Guideline on the choice of the non-inferiority margin. London; UK.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf
, last accessed on 12/20/2018.
4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2006). ICH topic E9 - Statistical Principles for Clinical Trials. Geneva, Switzerland.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf
, last accessed on 12/20/2018.
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2006). ICH Topic E10 - Choice of Control Group and Related Issues in Clinical Trials. Geneva, Switzerland.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf
, last accessed on 12/20/2018.